Similar articles

• [Treatment of ascites in hepatic cirrhosis].

  Arroyo JL, Bueno J, Rivero A, Lucas I, Ortiz de Landazuri E. Arroyo JL, et al. Rev Esp Enferm Apar Dig. 1966 Nov;25(9):1021-46. Rev Esp Enferm Apar Dig. 1966. PMID: 5997895 Spanish. No abstract available.
• [Management of hepatic ascites using Fursemide].

  Bemvenuti GA, Job JM. Bemvenuti GA, et al. Hospital (Rio J). 1968 Nov;74(5):1601-38. Hospital (Rio J). 1968. PMID: 5305338 Portuguese. No abstract available.
• Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study.

  Thuluvath PJ, Maheshwari A, Wong F, Yoo HW, Schrier RW, Parikh C, Steare S, Korula J. Thuluvath PJ, et al. Aliment Pharmacol Ther. 2006 Sep 15;24(6):973-82. doi: 10.1111/j.1365-2036.2006.03088.x. Aliment Pharmacol Ther. 2006. PMID: 16948809 Clinical Trial.
• Spironolactone and frusemide in cirrhosis with ascites.

  Sadikali F. Sadikali F. Br J Clin Pract. 1973 Jun;27(6):222-4. Br J Clin Pract. 1973. PMID: 4582147 Clinical Trial. No abstract available.
• [The diuretic effect of demethylchlortetracycline in non-compensated hepatic cirrhosis].

  Ronchi E, Cattani F, Croce G, Magri F, Cappellini F, Rosati R, Lucchelli PD. Ronchi E, et al. Recenti Prog Med. 1981 Apr;70(4):418-32. Recenti Prog Med. 1981. PMID: 6789413 Review. Italian. No abstract available.